One-month TB pill regimen tested for kidney transplant hopefuls
NCT ID NCT05411744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a 1-month course of three medicines (isoniazid, rifapentine, and vitamin B6) to treat latent tuberculosis in 25 adults with end-stage kidney disease who are candidates for a kidney transplant. The goal is to see if this shorter treatment is safe and easy to complete. Participants take the pills daily for 28 days, and researchers track side effects and how many doses are taken.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pinki J Bhatt
New Brunswick, New Jersey, 08901, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- Can a once-weekly TB pill safely mix with HIV treatment in kids?
- A regenerative graft could rethink dialysis access